Literature DB >> 22481455

Association between butyrylcholinesterase activity and low-grade systemic inflammation.

Natalia Lampón1, Esperanza F Hermida-Cadahia, Alberto Riveiro, J Carlos Tutor.   

Abstract

BACKGROUND: Pro-inflammatory cytokine production is directly inhibited by acetylcholine (ACh), and a relationship between total circulating ACh hydrolytic capacity and inflammatory reactions has been previously reported. Butyrylcholinesterase (BChE) is the major ACh hydrolyzing enzyme in plasma, and the aim of our study was to evaluate its association with low-grade systemic inflammation.
MATERIAL AND METHODS: A total of 4,077 patients clinically managed in the Cardiology, Hypertension, and Digestive Medicine Units were included in our study. Three subclinical chronic inflammatory degrees were established in accordance with the high-sensitivity C-reactive protein (hsCRP) concentrations proposed, for low (< 1 mg/L), average (1-3 mg/L), and high (> 3-10 mg/L) cardiovascular disease risk estimation.
RESULTS: In male patients with subclinical chronic inflammation and hsCRP concentrations < 1 mg/L, a significant positive correlation was observed between BChE and hsCRP (p < 0.02); however, for hsCRP concentrations > 3 mg/L, the correlation between these variables in both sexes becomes significantly negative (p < 0.001), as in patients with acute inflammation (hsCRP > 10 mg/L). In all cases significant positive correlations were obtained between the BChE activities and albumin concentrations (p < 0.001).
CONCLUSIONS: The liver production of BChE and albumin occurs in a coupled fashion, and these biochemical variables may be considered as negative inflammatory reactants, whose serum levels are inversely associated with the increasing degree of subclinical inflammation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22481455

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  32 in total

1.  The enigmatic role of cholinergic reflex in the pathogenesis of Chagas disease.

Authors:  Luiz G F de A B D'Elia Zanella; Agnaldo Bruno Chies; Maria Angélica Spadella; Altino Luiz Silva Therezo; Patrícia de Souza Rossignoli; Fernando Frei; Luciamáre Perinetti Alves Martins
Journal:  Parasitol Res       Date:  2014-04-01       Impact factor: 2.289

Review 2.  Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease and type 2 diabetes mellitus.

Authors:  Gohar Mushtaq; Nigel H Greig; Jalaluddin A Khan; Mohammad A Kamal
Journal:  CNS Neurol Disord Drug Targets       Date:  2014       Impact factor: 4.388

3.  Selective acetyl- and butyrylcholinesterase inhibitors reduce amyloid-β ex vivo activation of peripheral chemo-cytokines from Alzheimer's disease subjects: exploring the cholinergic anti-inflammatory pathway.

Authors:  Marcella Reale; Marta Di Nicola; Lucia Velluto; Chiara D'Angelo; Erica Costantini; Debomoy K Lahiri; Mohammad A Kamal; Qian-sheng Yu; Nigel H Greig
Journal:  Curr Alzheimer Res       Date:  2014       Impact factor: 3.498

4.  Drop of Butyrylcholinesterase Activity after Cyclophosphamide Conditioning as a Predictive Marker of Liver Transplant-Related Complications and Its Correlation with Transplant-Related Mortality in Pediatric Hematopoietic Stem Cell Recipients.

Authors:  Natalia Maximova; Giulia Caddeo; Davide Zanon; Alessandra Maestro; Roberto Simeone
Journal:  J Clin Med       Date:  2019-06-10       Impact factor: 4.241

5.  Alterations in acetylcholinesterase and butyrylcholinesterase activities in chronic obstructive pulmonary disease: relationships with oxidative and inflammatory markers.

Authors:  Amel Ben Anes; Hela Ben Nasr; Abdelhamid Garrouch; Sarra Bennour; Sarra Bchir; Mohamed Hachana; Mohamed Benzarti; Zouhair Tabka; Karim Chahed
Journal:  Mol Cell Biochem       Date:  2017-12-12       Impact factor: 3.396

6.  Butyrylcholinesterase Deficiency Promotes Adipose Tissue Growth and Hepatic Lipid Accumulation in Male Mice on High-Fat Diet.

Authors:  Vicky Ping Chen; Yang Gao; Liyi Geng; Michael B Stout; Michael D Jensen; Stephen Brimijoin
Journal:  Endocrinology       Date:  2016-06-14       Impact factor: 4.736

7.  Pretreatment serum pseudocholinesterase level as a novel prognostic biomarker for upper tract urothelial carcinoma.

Authors:  Bo Zhang; Cheng Shen; Jie Jin; Yi Song; Zheng Zhao; Xiaochun Zhang; Gang Wang; Yu Fan; Yue Mi; Shuai Hu; Yun Cui; Liqun Zhou; Zhisong He; Wei Yu; Wenke Han
Journal:  Int Urol Nephrol       Date:  2016-08-23       Impact factor: 2.370

8.  Low serum butyrylcholinesterase is independently related to low fetuin-A in patients on hemodialysis: a cross-sectional study.

Authors:  Teppei Okamoto; Chikako Tsutaya; Shingo Hatakeyama; Sakae Konishi; Kazutaka Okita; Yoshimi Tanaka; Kengo Imanishi; Tooru Takashima; Fumitada Saitoh; Tadashi Suzuki; Chikara Ohyama
Journal:  Int Urol Nephrol       Date:  2018-08-20       Impact factor: 2.370

9.  Significance of preoperative butyrylcholinesterase as an independent predictor of biochemical recurrence-free survival in patients with prostate cancer treated with radical prostatectomy.

Authors:  Takuya Koie; Chikara Ohyama; Shingo Hatakeyama; Atsushi Imai; Takahiro Yoneyama; Yasuhiro Hashimoto; Tohru Yoneyama; Yuki Tobisawa; Shogo Hosogoe; Hayato Yamamoto; Masato Kitayama; Kazuyoshi Hirota
Journal:  Int J Clin Oncol       Date:  2015-07-30       Impact factor: 3.402

10.  Butyrylcholinesterase level as an independent factor of erythropoiesis-stimulating agent resistance in patients on maintenance hemodialysis: a single-center cross-sectional study.

Authors:  Teppei Okamoto; Shingo Hatakeyama; Yoshimi Tanaka; Kengo Imanishi; Tooru Takashima; Fumitada Saitoh; Takuya Koie; Tadashi Suzuki; Chikara Ohyama
Journal:  Clin Exp Nephrol       Date:  2018-03-29       Impact factor: 2.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.